Company Aggregate Debt: Predictive Oncology Inc (POAI)

Predictive Oncology creates an AI environment for personalized cancer therapy selection. Total credit obligations visualize the financial burden, where the latest mark stands at 0.00. The stability of 3D modeling system deliveries guarantees order fulfillment. Growth in B2B subscriptions and the development of the CoRE platform accelerate the discovery of new drugs, ensuring the company's sustainable development in the medtech market.

Company Aggregate Debts: Predictive Oncology Inc (POAI) for 07/04/2022 - 12/12/2025

Metric breakdowns and analytics for Predictive Oncology (POAI)

- price and consensus price forecast:

Market Price predictive-oncology.com|POAI - Analyst Consensus Forecast

- market capitalization data:

Market Capitalization Predictive Oncology Corp|POAI - Enterprise Value

- book capitalization data:

Net Assets per Share Predictive Oncology|POAI - Book Capitalization|Market Cap to Net Assets Ratio predictive-oncology.com|POAI - Company Total Assets

- debt and liquidity data:

Total Debt to Capital Predictive Oncology|POAI - Long-Term Debt to Equity|Short-Term Debt to Equity predictive-oncology.com|POAI - Company Total Debt|Debt to Net Assets Ratio Predictive Oncology Corp

Basic company analysis:POAI Predictive Oncology Inc

Product sample of predictive-oncology.com

Stable rental income for Predictive Oncology (POAI) from long-term contracts with pharma behemoths allows the company to minimize its reliance on external financing. This metric aggregates all current obligations in real-time, reflecting the actual debt load and the cost of borrowed capital; therefore, analyzing the volume of borrowed funds helps investors assess the balance between financial stability and the pace of business scaling.

Key competitors